US Patent Issued to KOC UNIVERSITESI on Feb. 24 for "2-[2-({12,12-dimethyl-4-oxo-6-phenyl-3,11-dioxatricyclo[8.4.0.0,2,7tetradeca-1,5,7,9-tetraen-8-yl}oxy)acetamidobenzamide and derivatives as inhibitor of clock:bmal1 interaction for the treatment of circadian rhythm diseases and disorders" (Turkish Inventors)

ALEXANDRIA, Va., Feb. 24 -- United States Patent no. 12,558,342, issued on Feb. 24, was assigned to KOC UNIVERSITESI (Istanbul).

"2-[2-({12,12-dimethyl-4-oxo-6-phenyl-3,11-dioxatricyclo[8.4.0.0,2,7tetradeca-1,5,7,9-tetraen-8-yl}oxy)acetamidobenzamide and derivatives as inhibitor of clock:bmal1 interaction for the treatment of circadian rhythm diseases and disorders" was invented by Ibrahim Halil Kavakli (Istanbul), Metin Turkay (Istanbul), Yagmur Umay Doruk (Istanbul) and Darya Yarparvar (Istanbul).

According to the abstract* released by the U.S. Patent & Trademark Office: "A 2-[2-({12,12-dimethyl-4-oxo-6-phenyl-3,11-dioxatricyclo[8.4.0.0,2,7]tetradeca-1,5,7,9-tetraen-8-yl}oxy)acetamido]benzamide compound and related derivatives, as well ...